Program of International Asidan Symposium on Asida River/Japan (6 June, 2016)
Jun 17, 2016 updated

Friday, July 1. 2016
Time & chair Session # Speaker Title
pm 0:00 - 1:30 Lunch buffet free
pm 1:00 - 3:00 Symposium 1 (Asidan/SCA36 in the World, 15 + 5 min.)

Shoji Tsuji
(Tokyo)

Junichi Kira
(Fukuoka)
1 Koji Abe
(Okayama, Japan)
Clinical features and Pathogenesis of Asidan in Japan
2 Manuel Arias
(SdC, Spain)
Clinical characterization of SCA36-Costa da Morte ataxia families in Galicia-Spain
3 Bing-Wen Soong
(Taipei, Taiwan)
Clinical and molecular characterization of Asidan/SCA36 in Taiwan
4 Shoji Tsuji
(Tokyo, Japan)
Haplotype analysis of Asidan/SCA36
pm 3:00 - 3:30 Coffee break
pm 3:30 - 5:00 Symposium 2 (SCA/ALS/dementia, 15 + 5 min.)

Hidehiro Mizusawa
(Tokyo)

Masatoyo Nishizawa
(Niigata)
5 Hidenao Sasaki
(Sapporo, Japan)
Clinical feature and causative mutations of SCA14 in Hokkaido
6 Hidehiro Mizusawa
(Tokyo, Japan)
Clinical features and Pathogenesis of SCA31
7 Yi-Chung Lee
(Taipei, Taiwan)
ALS genetics in Taiwan
8 Mikio Shoji
(Hirosaki, Japan)
Genetics and Pathogenesis of Dementia in Japan
pm 5:00 - 6:30 Excursion to Asida river and group photo
pm 6:30 - 7:00 Break
pm 7:00 - 8:00 Special Lecture

Ryosuke Takahashi
(Kyoto)

Hiroshi Takashima
(Kagoshima)
7:00 - 7:10 Koji Abe
(Okayama, Japan)
Overview: Discovery of Asidan/SCA36 and potential multisystem involvement with DWEP
7:10 - 8:00 Maria-Jesus Sobrido
(SdC, Spain)
Genetic studies of SCA36 Cosa da Morte patients
pm 8:00 - 9:30 Welcome Reception

Saturday, July 2. 2016
Time & chair Session # Speaker Title
am 8:10 - 9:00 Oral presentation (3 + 2 min.)

Yoshitaka Nagai
(Osaka)

Yasumasa Kokubo
(Mie)
9 Yusuke Fukui
(Okayama, Japan)
Characteristic diffusion tensor tractography in MSA-C and CCA
10 Yumiko Nakano
(Okayama, Japan)
High conversion of post-stroke patients into dementia in an elder country
11 Ryuta Morihara
(Okayama, Japan)
Progressive Alzheimer’s pathology after cerebral ischemia in rats
12 Syoichiro Kono
(Okayama, Japan)
A case of spinocerebellar ataxia with involvement of the motor neuron system
13 Kosuke Matsuzono
(Okayama, Japan)
Modeling Asidan/SCA36 using patient iPSCs for therapy development
14 Qian Li
(Okayama, Japan)
C9ALS-related RanGap1 expression after cerebral ischemia mice
15 Toru Yamashita
(Okayama, Japan)
Assessment of swallowing in Asidan patients with novel methods
16 Jingwei Shang
(Okayama, Japan)
C9ALS-related RanGap1 expression in ALS mice
17 Yasuyuki Ohta
(Okayama, Japan)
Acoustic impairment is a distinguishable clinical feature of Asidan
am 9:00 - 10:00 Symposium 3 (ALS/PDC and Polynucleotide Expansions, 10 + 2 min.)

Hidenao Sasaki
(Sapporo)

Masashi Aoki
(Sendai)
18 Yasumasa Kokubo
(Mie, Japan)
Clinical features of Kii ALS/PDC
19 Ryuichi Ohkubo
(Kagoshima, Japan)
Clinical characteristics of Asidan in South Kyushu
20 Yi-Chu Liao
(Taipei, Taiwan)
Clinical and molecular characterization of SCA36 in Taiwan
21 Zachary Mceachin
(Atlanta, USA)
iPS cell technology in Asidan/SCA36
22 Yoshitaka Nagai
(Osaka, Japan)
Fly model of C9-ALS/FTD
am 10:00 - 12:00 Symposium 4 (Molecular Mechanisms and Therapeutic Target, 15 + 5 min.)

Shigeki Kuzuhara
(Suzuka)

Gen Sobue
(Nagoya)
23 Yoshio Ikeda
(Maebashi, Japan)
Pathology and pathogenesis of Asidan
24 Wilfried Rossoll
(Atlanta, USA)
Disease mechanisms in SCA36/Asidan and C9ALS
25 Hong-Lin Su
(Taichung, Taiwan)
The neuroprotection of butylidenephthalide on AD-like iPSCs and SAMP8 mice
26 Masahisa Katsuno
(Nagoya, Japan)
Potential therapeutic targets in polyglutamine-mediated diseases
27 Makoto Urushitani
(Shiga, Japan)
Molecular epitopes for pathogenic TDP-43; a promising therapeutic target in ALS
28 Kinya Ishikawa
(Tokyo, Japan)
Molecular pathogenesis revealed through SCA31 BEAN1-models
am 12:00 - Lunch buffet (free) and Adjourn

"The participation of Dr. Sobrido and Dr. Arias in this meeting was supported by the ISCIII grants PI12/00742 and PI12/01013, respectively, co-financed with FEDER funds".